Skip to main content
SpringerLink
Log in

State of the Art Medical Treatment of the Adult Patient with IBD: The Mesalamine-Based Therapies

  • Chapter
  • First Online:
Inflammatory Bowel Disease

Part of the book series: Clinical Gastroenterology ((CG))

  • 1791 Accesses

Abstract

Mesalamine-based therapies have been used for Crohn’s disease and ulcerative colitis for over six decades with a long track record of safety. Despite multiple studies over years that demonstrated some efficacy of aminosalicylates in Crohn’s disease, a more critical review of the literature reveals little if any benefit. Effective for the induction and maintenance of remission for ulcerative colitis, oral aminosalicylates are the drugs of choice for mild to moderate extensive UC. There is no evidence that a single aminosalicylate formulation is clearly superior to the others. However, convenient dosing regimens enabled by the newer formulations may have an impact on adherence to therapy. Current data suggest that 5-aminosalicylic acids (5-ASA) may have a chemoprotective effect against colorectal cancer though further study is needed.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 229.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 299.00
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Svartz N. Salazopyrin, a new sulfaniliamide preparation: A. Therapeutic results in rheumatic polyarthritis. B. Therapeutic results in ulcerative colitis. C. Toxic manifestations in treatment with sulfanilamide preparation. Acta Med Scand. 1942;110:557–90.

    Google Scholar 

  2. Azad Khan AK, Piris J, Truelove SC. An experiment to determine the active therapeutic moiety of sulphasalazine. Lancet. 1977;2(8044):892–5.

    Article  PubMed  CAS  Google Scholar 

  3. Peppercorn MA, Goldman P. The role of intestinal bacteria in the metabolism of salicylazosulfapyridine. J Pharmacol Exp Ther. 1972;181(3):555–62.

    PubMed  CAS  Google Scholar 

  4. Nielsen OH, Munck LK. Drug insight: aminosalicylates for the treatment of IBD. Nat Clin Pract Gastroenterol Hepatol. 2007;4(3):160–70.

    Article  PubMed  CAS  Google Scholar 

  5. Sandborn WJ, Hanauer SB. Systematic review: the pharmacokinetic profiles of oral mesalazine formulations and mesalazine pro-drugs used in the management of ulcerative colitis. Aliment Pharmacol Ther. 2003;17(1):29–42.

    Article  PubMed  CAS  Google Scholar 

  6. Sandborn WJ, Balan G, Kuzmak B. Comparable pharmacokinetics (PK) of two delayed release formulations of oral mesalamine. Am J Gastroenterol. 2007;103(Suppl 2):S465 (abstract 944).

    Google Scholar 

  7. Stenson WF, Lobos E. Sulfasalazine inhibits the synthesis of chemotactic lipids by neutrophils. J Clin Invest. 1982;69(2):494–7.

    Article  PubMed  CAS  Google Scholar 

  8. Ahnfelt-Ronne I, Nielsen OH, Christensen A, Langholz E, Binder V, Riis P. Clinical evidence supporting the radical scavenger mechanism of 5-aminosalicylic acid. Gastroenterology. 1990;98(5 Pt 1):1162–9.

    PubMed  CAS  Google Scholar 

  9. Nielsen OH, Verspaget HW, Elmgreen J. Inhibition of intestinal macrophage chemotaxis to leukotriene B4 by sulphasalazine, olsalazine, and 5-aminosalicylic acid. Aliment Pharmacol Ther. 1988;2(3):203–11.

    Article  PubMed  CAS  Google Scholar 

  10. Kim H, Jeon H, Kong H, Yang Y, Choi B, Kim YM, et al. A molecular mechanism for the anti-inflammatory effect of taurine-conjugated 5-aminosalicylic acid in inflamed colon. Mol Pharmacol. 2006;69(4):1405–12.

    Article  PubMed  CAS  Google Scholar 

  11. Kaiser GC, Yan F, Polk DB. Mesalamine blocks tumor necrosis factor growth inhibition and nuclear factor kappaB activation in mouse colonocytes. Gastroenterology. 1999;116(3):602–9.

    Article  PubMed  CAS  Google Scholar 

  12. Linard C, Gremy O, Benderitter M. Reduction of peroxisome proliferation-activated receptor gamma expression by gamma-irradiation as a mechanism contributing to inflammatory response in rat colon: modulation by the 5-aminosalicylic acid agonist. J Pharmacol Exp Ther. 2008;324(3):911–20.

    Article  PubMed  CAS  Google Scholar 

  13. Kane SV, Bjorkman DJ. The efficacy of oral 5-ASAs in the treatment of active ulcerative colitis: a systematic review. Rev Gastroenterol Disord. 2003;3(4):210–8.

    PubMed  Google Scholar 

  14. Pentasa (mesalamine) Controlled-Release Capsules (prescribing information). Available at: http://pi.shirecontent.com/PI/PDFs/Pentasa_USA_ENG.pdf. Accessed January 17, 2011.

  15. Asacol (mesalamine) Delayed-Release Tablets (prescribing information). Available at: http://www.asacol.com/pdf/asacol-info.pdf. Accessed January 17, 2011.

  16. Lialda (mesalamine) Delayed Release Tablets (prescribing information). Available at: http://pi.shirecontent.com/PI/PDFs/Lialda_USA_ENG.pdf. Accessed January 17, 2011.

  17. Colazal Physician Resource Center. Salix Pharmaceuticals, Inc; 2008 [updated 2008; cited 1 July 2008]; Available from: http://www.salix.com/products/colazal/physician/about.aspx.

  18. Sutherland L, Macdonald JK. Oral 5-aminosalicylic acid for maintenance of remission in ulcerative colitis. Cochrane Database Syst Rev. 2006;(2):CD000544.

    Google Scholar 

  19. Cunliffe RN, Scott BB. Review article: monitoring for drug side-effects in inflammatory bowel disease. Aliment Pharmacol Ther. 2002;16(4):647–62.

    Article  PubMed  CAS  Google Scholar 

  20. Nielsen OH. Sulfasalazine intolerance. A retrospective survey of the reasons for discontinuing treatment with sulfasalazine in patients with chronic inflammatory bowel disease. Scand J Gastroenterol. 1982;17(3):389–93.

    Article  PubMed  CAS  Google Scholar 

  21. Hanauer SB, Sandborn WJ, Kornbluth A, Katz S, Safdi M, Woogen S, et al. Delayed-release oral mesalamine at 4.8 g/day (800 mg tablet) for the treatment of moderately active ulcerative colitis: the ASCEND II trial. Am J Gastroenterol. 2005;100(11):2478–85.

    Article  PubMed  CAS  Google Scholar 

  22. Loftus Jr EV, Kane SV, Bjorkman D. Systematic review: short-term adverse effects of 5-aminosalicylic acid agents in the treatment of ulcerative colitis. Aliment Pharmacol Ther. 2004;19(2):179–89.

    Article  PubMed  CAS  Google Scholar 

  23. Ransford RA, Langman MJ. Sulphasalazine and mesalazine: serious adverse reactions re-evaluated on the basis of suspected adverse reaction reports to the Committee on Safety of Medicines. Gut. 2002;51(4):536–9.

    Article  PubMed  CAS  Google Scholar 

  24. Gisbert JP, Gonzalez-Lama Y, Mate J. 5-Aminosalicylates and renal function in inflammatory bowel disease: a systematic review. Inflamm Bowel Dis. 2007;13(5):629–38.

    Article  PubMed  Google Scholar 

  25. Nelis GF. Diarrhoea due to 5-aminosalicylic acid in breast milk. Lancet. 1989;1(8634):383.

    Article  PubMed  CAS  Google Scholar 

  26. Mahadevan U, Kane S. American gastroenterological association institute technical review on the use of gastrointestinal medications in pregnancy. Gastroenterology. 2006;131(1):283–311.

    Article  PubMed  CAS  Google Scholar 

  27. Riley SA, Lecarpentier J, Mani V, Goodman MJ, Mandal BK, Turnberg LA. Sulphasalazine induced seminal abnormalities in ulcerative colitis: results of mesalazine substitution. Gut. 1987;28(8):1008–12.

    Article  PubMed  CAS  Google Scholar 

  28. Summers RW, Switz DM, Sessions Jr JT, Becktel JM, Best WR, Kern Jr F, et al. National Cooperative Crohn’s Disease Study: results of drug treatment. Gastroenterology. 1979;77(4 Pt 2):847–69.

    PubMed  CAS  Google Scholar 

  29. Singleton JW, Hanauer SB, Gitnick GL, Peppercorn MA, Robinson MG, Wruble LD, et al.; Pentasa Crohn’s Disease Study Group. Mesalamine capsules for the treatment of active Crohn’s disease: results of a 16-week trial. Gastroenterology. 1993;104(5):1293–301.

    Google Scholar 

  30. Tremaine WJ, Schroeder KW, Harrison JM, Zinsmeister AR. A randomized, double-blind, placebo-controlled trial of the oral mesalamine (5-ASA) preparation, Asacol, in the treatment of symptomatic Crohn’s colitis and ileocolitis. J Clin Gastroenterol. 1994;19(4):278–82.

    Article  PubMed  CAS  Google Scholar 

  31. Camma C, Giunta M, Rosselli M, Cottone M. Mesalamine in the maintenance treatment of Crohn’s disease: a meta-analysis adjusted for confounding variables. Gastroenterology. 1997;113(5):1465–73.

    Article  PubMed  CAS  Google Scholar 

  32. Lochs H, Mayer M, Fleig WE, Mortensen PB, Bauer P, Genser D, et al. Prophylaxis of postoperative relapse in Crohn’s disease with mesalamine: European Cooperative Crohn’s Disease Study VI. Gastroenterology. 2000;118(2):264–73.

    Article  PubMed  CAS  Google Scholar 

  33. Hanauer SB, Korelitz BI, Rutgeerts P, Peppercorn MA, Thisted RA, Cohen RD, et al. Postoperative maintenance of Crohn’s disease remission with 6-mercaptopurine, mesalamine, or placebo: a 2-year trial. Gastroenterology. 2004;127(3):723–9.

    Article  PubMed  CAS  Google Scholar 

  34. Hanauer SB, Stromberg U. Oral Pentasa in the treatment of active Crohn’s disease: a meta-analysis of double-blind, placebo-controlled trials. Clin Gastroenterol Hepatol. 2004;2(5):379–88.

    Article  PubMed  CAS  Google Scholar 

  35. Akobeng AK, Gardener E. Oral 5-aminosalicylic acid for maintenance of medically-induced remission in Crohn’s disease. Cochrane Database Syst Rev. 2005;(1):CD003715.

    Google Scholar 

  36. Hanauer SB, Sandborn W. Management of Crohn’s disease in adults. Am J Gastroenterol. 2001;96(3):635–43.

    Article  PubMed  CAS  Google Scholar 

  37. Lichtenstein GR, Abreu MT, Cohen R, Tremaine W. American Gastroenterological Association Institute medical position statement on corticosteroids, immunomodulators, and infliximab in inflammatory bowel disease. Gastroenterology. 2006;130(3):935–9.

    Article  PubMed  Google Scholar 

  38. Travis SP, Stange EF, Lemann M, Oresland T, Chowers Y, Forbes A, et al. European evidence based consensus on the diagnosis and management of Crohn’s disease: current management. Gut. 2006;55 Suppl 1:i16–35.

    Article  PubMed  Google Scholar 

  39. Sandborn WJ, Feagan BG, Lichtenstein GR. Medical management of mild to moderate Crohn’s disease: evidence-based treatment algorithms for induction and maintenance of remission. Aliment Pharmacol Ther. 2007;26(7):987–1003.

    Article  PubMed  CAS  Google Scholar 

  40. Sutherland L, Macdonald JK. Oral 5-aminosalicylic acid for induction of remission in ulcerative colitis. Cochrane Database Syst Rev. 2006;(2):CD000543.

    Google Scholar 

  41. Cohen RD, Woseth DM, Thisted RA, Hanauer SB. A meta-analysis and overview of the literature on treatment options for left-sided ulcerative colitis and ulcerative proctitis. Am J Gastroenterol. 2000;95(5):1263–76.

    Article  PubMed  CAS  Google Scholar 

  42. Marteau P, Probert CS, Lindgren S, Gassul M, Tan TG, Dignass A, et al. Combined oral and enema treatment with Pentasa (mesalazine) is superior to oral therapy alone in patients with extensive mild/moderate active ulcerative colitis: a randomised, double blind, placebo ­controlled study. Gut. 2005;54(7):960–5.

    Article  PubMed  CAS  Google Scholar 

  43. Safdi AV, Cohen RD. Review article: increasing the dose of oral mesalazine therapy for active ulcerative colitis does not improve remission rates. Aliment Pharmacol Ther. 2007;26(9):1179–86.

    Article  PubMed  CAS  Google Scholar 

  44. Sandborn WJ, Regula J, Feagan BG, Belousova EA, Jojic NV, Yacyshyn BR, et al. Efficacy and safety of delayed-release oral mesalamine at 4.8 g/d (800 mg tablet) in the treatment of moderately active ulcerative colitis: results of the ASCEND III study. Gastroenterology. 2008;134(Suppl 1):A-99 (abstract 702).

    Google Scholar 

  45. Katz S, Yacyshyn B, Ramsey DL, Lichtenstein GR. Previous history of steroid use does not preclude treatment with mesalamine in uclerative colitis (UC). Am J Gastroenterol. 2007;102(Suppl 2):S465 (abstract 945).

    Google Scholar 

  46. Hanauer SB. Review article: evolving concepts in treatment and disease modification in ulcerative colitis. Aliment Pharmacol Ther. 2008;27 Suppl 1:15–21.

    Article  PubMed  Google Scholar 

  47. Kamm MA, Sandborn WJ, Gassull M, Schreiber S, Jackowski L, Butler T, et al. Once-daily, high-concentration MMX mesalamine in active ulcerative colitis. Gastroenterology. 2007;132(1):66–75.

    Google Scholar 

  48. Kane S, Huo D, Aikens J, Hanauer S. Medication nonadherence and the outcomes of patients with quiescent ulcerative colitis. Am J Med. 2003;114(1):39–43.

    Article  PubMed  Google Scholar 

  49. Loftus Jr EV. A practical perspective on ulcerative colitis: patients’ needs from aminosalicylate therapies. Inflamm Bowel Dis. 2006;12(12):1107–13.

    Article  PubMed  Google Scholar 

  50. Carter MJ, Lobo AJ, Travis SP. Guidelines for the management of inflammatory bowel disease in adults. Gut. 2004;53 Suppl 5:V1–16.

    Article  PubMed  Google Scholar 

  51. Kornbluth A, Sachar DB. Ulcerative colitis practice guidelines in adults (update): American College of Gastroenterology, Practice Parameters Committee. Am J Gastroenterol. 2004;99(7):1371–85.

    Article  PubMed  Google Scholar 

  52. Eaden JA, Abrams KR, Mayberry JF. The risk of colorectal cancer in ulcerative colitis: a meta-analysis. Gut. 2001;48(4):526–35.

    Article  PubMed  CAS  Google Scholar 

  53. Gupta RB, Harpaz N, Itzkowitz S, Hossain S, Matula S, Kornbluth A, et al. Histologic inflammation is a risk factor for progression to colorectal neoplasia in ulcerative colitis: a cohort study. Gastroenterology. 2007;133(4):1099–105.

    Google Scholar 

  54. Jess T, Loftus Jr EV, Velayos FS, Harmsen WS, Zinsmeister AR, Smyrk TC, et al. Risk of intestinal cancer in inflammatory bowel disease: a population-based study from olmsted county, Minnesota. Gastroenterology. 2006;130(4):1039–46.

    Article  PubMed  Google Scholar 

  55. Rutter MD, Saunders BP, Wilkinson KH, Rumbles S, Schofield G, Kamm MA, et al. Thirty-year analysis of a colonoscopic surveillance program for neoplasia in ulcerative colitis. Gastroenterology. 2006;130(4):1030–8.

    Article  PubMed  Google Scholar 

  56. Lutgens MW, van der Heijden GJ, Vleggar FP, Oldenburg B. A comprehensive meta-analysis of the risk of colorectal cancer in ulcerative colitis and Crohn’s disease. Gastroenterology. 2008;134(Suppl 1):A-33 (abstract 194).

    Google Scholar 

  57. Rubin DT, Cruz-Correa MR, Gasche C, Jass JR, Lichtenstein GR, Montgomery EA, et al. Colorectal cancer prevention in inflammatory bowel disease and the role of 5-aminosalicylic acid: a clinical review and update. Inflamm Bowel Dis. 2008;14(2):265–74.

    Article  PubMed  Google Scholar 

  58. Siegel CA, Sands BE. Risk factors for colorectal cancer in Crohn’s colitis: a case-control study. Inflamm Bowel Dis. 2006;12(6):491–6.

    Article  PubMed  Google Scholar 

Download references

Acknowledgment

The authors would like to thank Dr. Miles Sparrow for his help in the research and referencing process of this chapter.

Author information

Authors and Affiliations

  1. Section of Gastroenterology and Hepatology, Dartmouth-Hitchcock Medical Center, Lebanon, NH, 03756, USA

    Corey A. Siegel

Authors
  1. L. Campbell Levy
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Corey A. Siegel
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Corey A. Siegel .

Editor information

Editors and Affiliations

  1. MC 4076, Sect. Of GE, Hepatol. & Nutr., Department of Medicine, University of Chicago Medical Center, S. Maryland Ave. 5841, Chicago, 60637, Illinois, USA

    Russell D. Cohen

Rights and permissions

Reprints and permissions

Copyright information

© 2011 Springer Science+Business Media, LLC

About this chapter

Cite this chapter

Levy, L.C., Siegel, C.A. (2011). State of the Art Medical Treatment of the Adult Patient with IBD: The Mesalamine-Based Therapies. In: Cohen, R. (eds) Inflammatory Bowel Disease. Clinical Gastroenterology. Humana Press, Totowa, NJ. https://doi.org/10.1007/978-1-60327-433-3_5

Download citation

  • DOI: https://doi.org/10.1007/978-1-60327-433-3_5

  • Published:

  • Publisher Name: Humana Press, Totowa, NJ

  • Print ISBN: 978-1-60327-432-6

  • Online ISBN: 978-1-60327-433-3

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation